121 related articles for article (PubMed ID: 20462760)
1. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
2. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
3. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
Ginn JD; Bosanac T; Chen R; Cywin C; Hickey E; Kashem M; Kerr S; Kugler S; Li X; Prokopowicz A; Schlyer S; Smith JD; Turner MR; Wu F; Young ER
Bioorg Med Chem Lett; 2010 Sep; 20(17):5153-6. PubMed ID: 20678931
[TBL] [Abstract][Full Text] [Related]
4. Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
Morwick T; Büttner FH; Cywin CL; Dahmann G; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Mao W; Marshall D; Paw Z; Shih CK; Wu F; Young E
J Med Chem; 2010 Jan; 53(2):759-77. PubMed ID: 20000469
[TBL] [Abstract][Full Text] [Related]
5. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
[TBL] [Abstract][Full Text] [Related]
6. Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Ray P; Wright J; Adam J; Bennett J; Boucharens S; Black D; Cook A; Brown AR; Epemolu O; Fletcher D; Haunso A; Huggett M; Jones P; Laats S; Lyons A; Mestres J; de Man J; Morphy R; Rankovic Z; Sherborne B; Sherry L; van Straten N; Westwood P; Zaman GZ
Bioorg Med Chem Lett; 2011 Jan; 21(1):97-101. PubMed ID: 21145740
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).
Christopher JA; Bamborough P; Alder C; Campbell A; Cutler GJ; Down K; Hamadi AM; Jolly AM; Kerns JK; Lucas FS; Mellor GW; Miller DD; Morse MA; Pancholi KD; Rumsey W; Solanke YE; Williamson R
J Med Chem; 2009 May; 52(9):3098-102. PubMed ID: 19348415
[TBL] [Abstract][Full Text] [Related]
9. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
[TBL] [Abstract][Full Text] [Related]
11. Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1).
Asano Y; Kitamura S; Ohra T; Aso K; Igata H; Tamura T; Kawamoto T; Tanaka T; Sogabe S; Matsumoto S; Yamaguchi M; Kimura H; Itoh F
Bioorg Med Chem; 2008 Apr; 16(8):4715-32. PubMed ID: 18313304
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).
Sessions EH; Chowdhury S; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7113-8. PubMed ID: 22018789
[TBL] [Abstract][Full Text] [Related]
13. The development of benzimidazoles as selective rho kinase inhibitors.
Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J; Schröter T; Cameron MD; LoGrasso P; Feng Y; Bannister TD
Bioorg Med Chem Lett; 2010 Mar; 20(6):1939-43. PubMed ID: 20167489
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Ray P; Wright J; Adam J; Boucharens S; Black D; Brown AR; Epemolu O; Fletcher D; Huggett M; Jones P; Laats S; Lyons A; de Man J; Morphy R; Sherborne B; Sherry L; Straten Nv; Westwood P; York M
Bioorg Med Chem Lett; 2011 Feb; 21(4):1084-8. PubMed ID: 21251828
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
16. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
[TBL] [Abstract][Full Text] [Related]
17. Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition.
Schlüter T; Steinbach AC; Steffen A; Rettig R; Grisk O
Cardiovasc Res; 2008 Nov; 80(2):271-9. PubMed ID: 18596059
[TBL] [Abstract][Full Text] [Related]
18. Chroman-3-amides as potent Rho kinase inhibitors.
Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
[TBL] [Abstract][Full Text] [Related]
19. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.
Gong LL; Fang LH; Peng JH; Liu AL; Du GH
J Biotechnol; 2010 Feb; 145(3):295-303. PubMed ID: 19963024
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
